RHJA
EBS icon

Rice Hall James & Associates’s Emergent Biosolutions EBS Stock Holding History

Rice Hall James & Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,396
Closed -$1.12M – 268
2022
Q3 		$1.12M Sell
53,396
-208,137
-80% -$5.79M 0.07% 227
2022
Q2 		$8.12M Sell
261,533
-41,188
-14% -$1.41M 0.39% 63
2022
Q1 		$12.4M Sell
302,721
-40,626
-12% -$1.79M 0.5% 58
2021
Q4 		$14.9M Sell
343,347
-28,541
-8% -$1.29M 0.53% 50
2021
Q3 		$18.6M Sell
371,888
-35,459
-9% -$2.15M 0.69% 47
2021
Q2 		$25.7M Sell
407,347
-97,511
-19% -$6.26M 0.91% 36
2021
Q1 		$46.9M Sell
504,858
-82,869
-14% -$8.49M 1.53% 19
2020
Q4 		$52.7M Sell
587,727
-35,405
-6% -$3.25M 1.85% 12
2020
Q3 		$64.4M Sell
623,132
-39,217
-6% -$4.23M 2.59% 7
2020
Q2 		$52.4M Sell
662,349
-102,853
-13% -$7.66M 2.25% 7
2020
Q1 		$44.3M Sell
765,202
-335,563
-30% -$19.3M 2.47% 3
2019
Q4 		$59.4M Sell
1,100,765
-128,026
-10% -$6.94M 2.01% 3
2019
Q3 		$64.2M Buy
1,228,791
+25,125
+2% +$1.17M 2.3% 1
2019
Q2 		$58.1M Sell
1,203,666
-16,788
-1% -$805K 1.93% 6
2019
Q1 		$61.7M Sell
1,220,454
-135,495
-10% -$7.99M 1.99% 7
2018
Q4 		$80.4M Buy
1,355,949
+240,074
+22% +$15.5M 2.93% 1
2018
Q3 		$73.5M Sell
1,115,875
-25,146
-2% -$1.47M 2.63% 3
2018
Q2 		$57.6M Buy
1,141,021
+174,614
+18% +$9.1M 2.09% 4
2018
Q1 		$50.9M Buy
966,407
+197,311
+26% +$9.83M 1.99% 4
2017
Q4 		$35.7M Buy
769,096
+126,069
+20% +$5.31M 1.4% 11
2017
Q3 		$26M Sell
643,027
-26,590
-4% -$962K 1.15% 16
2017
Q2 		$22.7M Buy
669,617
+138,611
+26% +$4.28M 0.99% 23
2017
Q1 		$15.4M Buy
531,006
+140,906
+36% +$4.29M 0.75% 63
2016
Q4 		$12.8M Buy
390,100
+75,455
+24% +$2.26M 0.65% 69
2016
Q3 		$9.92M Buy
314,645
+35,418
+13% +$1.03M 0.52% 79
2016
Q2 		$7.85M Buy
279,227
+3,930
+1% +$154K 0.45% 82
2016
Q1 		$10M Buy
275,297
+5,746
+2% +$203K 0.58% 72
2015
Q4 		$10.8M Buy
269,551
+114,701
+74% +$4M 0.62% 68
2015
Q3 		$4.41M Buy
154,850
+62,630
+68% +$2.06M 0.29% 83
2015
Q2 		$3.04M Buy
+92,220
New +$2.86M 0.18% 131

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rice Hall James & Associates's EBS Position: Q4 2022 in Review

Rice Hall James & Associates sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 53,396 shares — an estimated $1.12M sold.

Rice Hall James & Associates first reported a position in EBS in Q2 2015 and held it in 30 quarters. The position peaked at $80.4M in Q4 2018. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Rice Hall James & Associates reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 53,396 Emergent Biosolutions shares in Q4 2022, an estimated $1.12M.
  • Rice Hall James & Associates first reported a position in Emergent Biosolutions in Q2 2015 and held it in 30 quarters.
  • Rice Hall James & Associates's Emergent Biosolutions position peaked at $80.4M in Q4 2018.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.